Ahmad S S, Rawala-Sheikh R, Walsh P N
Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania 19140.
J Biol Chem. 1989 Feb 25;264(6):3244-51.
Both factor IX and factor IXa were bound to gel filtered platelets in the presence of CaCl2 (2-20 mM) and human alpha-thrombin (0.06-0.2 units/ml) with maximal binding occurring in 10-20 min at 37 degrees C, and rapid reversibility was observed when unlabeled ligands were added in 100-fold molar excess. Competition studies with various coagulation proteins revealed that neither factor XI nor high molecular weight kininogen, at 300-fold molar excess, could compete with 125I-labeled factor IXa for binding sites on thrombin-activated platelets, whereas prothrombin and factor X, in 450-fold molar excess, could displace approximately 15 and 35%, respectively, of bound factor IXa in the absence of added factor VIII. Analysis of saturation binding data in the presence of CaCl2 and thrombin without factors VIII and X indicated the presence of 306 (+/- 57) binding sites per platelet for factor IX (Kd(app) = 2.68 +/- 0.25 nM) and 515 (+/- 39) sites per platelet for factor IXa (Kd = 2.57 +/- 0.14 nM). In the presence of thrombin-activated factor VIII (1-5 units/ml) and factor X (0.15-1.5 microM), the number of sites for factor IX was 316 (+/- 50) with Kd = 2.44 (+/- 0.30) nM and for factor IXa 551 (+/- 48) sites per platelet (Kd = 0.56 +/- 0.05 nM). Studies of competition for bound factor IXa by excess unlabeled factor IX or factor IXa, and direct 125I-labeled factor IXa binding studies in the presence of large molar excesses of factor IX, confirmed the conclusion from these studies that factor IX and factor IXa share approximately 300 low-affinity binding sites per thrombin-activated platelet in the presence of Ca2+ and in the absence of factor VIII and factor X, with an additional 200-250 sites for factor IXa with Kd(app) similar to that for factor IX. The presence of factor VIII and factor X increases by 5-fold the affinity of receptors on thrombin-activated platelets for factor IXa that participate in factor X activation.
在氯化钙(2 - 20 mM)和人α-凝血酶(0.06 - 0.2单位/毫升)存在的情况下,凝血因子IX和凝血因子IXa均与凝胶过滤后的血小板结合,在37℃下10 - 20分钟时结合达到最大值,当加入100倍摩尔过量的未标记配体时,观察到快速可逆性。用各种凝血蛋白进行的竞争研究表明,在300倍摩尔过量时,凝血因子XI和高分子量激肽原均不能与125I标记的凝血因子IXa竞争凝血酶激活血小板上的结合位点,而在450倍摩尔过量时,凝血酶原和凝血因子X分别可取代约15%和35%未添加凝血因子VIII时结合的凝血因子IXa。在不存在凝血因子VIII和X的情况下,对氯化钙和凝血酶存在时的饱和结合数据进行分析表明,每个血小板上凝血因子IX的结合位点有306(±57)个(Kd(app)=2.68±0.25 nM),凝血因子IXa的结合位点有515(±39)个(Kd = 2.57±0.14 nM)。在凝血酶激活的凝血因子VIII(1 - 5单位/毫升)和凝血因子X(0.15 - 1.5 microM)存在的情况下,凝血因子IX的结合位点数为316(±50)个,Kd = 2.44(±0.30)nM,凝血因子IXa每个血小板有551(±48)个结合位点(Kd = 0.56±0.05 nM)。用过量未标记的凝血因子IX或凝血因子IXa竞争结合的凝血因子IXa的研究,以及在大量摩尔过量凝血因子IX存在的情况下直接进行的125I标记凝血因子IXa结合研究,证实了这些研究的结论,即在Ca2+存在且不存在凝血因子VIII和凝血因子X的情况下,每个凝血酶激活的血小板上凝血因子IX和凝血因子IXa共享约300个低亲和力结合位点,凝血因子IXa还有另外200 - 250个结合位点,其Kd(app)与凝血因子IX相似。凝血因子VIII和凝血因子X的存在使凝血酶激活血小板上参与凝血因子X激活的凝血因子IXa受体的亲和力增加了5倍。